Type 2 Diabetes Trial, Recruiting NCT07660445 Sponsor: Chinese University of Hong Kong Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT07660445
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have a Body Mass Index (BMI) of 27 or higher (a measure of body weight relative to height)
  • You have been diagnosed with Type 2 diabetes
  • You have a specific score between 25 and 115 on a diabetes surgery suitability assessment called the IMS score (confirm with trial site)
  • Your average blood sugar level (HbA1c) is below 11% if you take diabetes tablets, or below 8% if you use insulin

Who may not be able to join:

  • You have previously had a similar stomach or gut procedure called ReCET, ESG, or equivalent
  • You have had previous stomach or bowel surgery, or currently have a stomach or duodenum (upper gut) condition that could make these procedures risky
  • You have Type 1 diabetes, diabetes caused by another illness, or have ever had a dangerous blood sugar emergency called ketoacidosis
  • Your fasting C-peptide level (a blood test related to insulin production) is too low (confirm with trial site)
  • You have an inflammatory bowel condition such as Crohn's disease
  • You have polyps, ulcers, or bleeding in the upper digestive tract within the last 3 months
  • You have a bleeding disorder, very low platelet count, or problems with blood clotting
  • You are taking blood-thinning medication within 10 days before the study, or expect to need it during the study
  • You are currently taking medications known to cause significant weight gain or weight loss, such as certain cancer treatments
  • You have used anti-inflammatory painkillers (NSAIDs) or steroid medications in the past month
  • You have an uncontrolled hormonal condition that causes weight gain, such as an underactive thyroid, Cushing's syndrome, or an eating disorder
  • You have a condition that makes endoscopy (a camera examination of the gut) unsafe for you
  • You have liver scarring (cirrhosis) caused by something other than a condition called MASLD (confirm with trial site)
  • You have or have had cancer
  • You have an autoimmune condition affecting connective tissue, such as lupus or scleroderma
  • You are pregnant or breastfeeding
  • You are classified as a very high anaesthetic risk (ASA grade IV or V — confirm with trial site)
  • You have a mental health condition, psychiatric disorder, or addiction to drugs or alcohol
  • Your doctor considers you unsuitable for safe treatment for any other reason
  • You do not wish to take part

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Stephen Ng, Prince of Wales Hospital, the Chinese University of Hong Kong

Phone: +85235052956

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 August 2026
Est. completion
31 July 2029

Where this trial is recruiting

Hong Kong

Primary endpoints

Change in Diabetic medications

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov